Fate Therapeutics, Inc. (FATE)
2.25
+0.15
(+7.14%)
USD |
NASDAQ |
May 22, 16:00
2.24
-0.01
(-0.44%)
After-Hours: 20:00
Fate Therapeutics EPS Diluted (Quarterly) : -0.26 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0211 |
| Alnylam Pharmaceuticals, Inc. | 1.508 |
| Amgen, Inc. | 3.344 |
| Savara, Inc. | -0.1472 |
| Biogen, Inc. | 2.153 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -31.21M |
| Revenue (Quarterly) | 1.299M |
| Total Expenses (Quarterly) | 32.51M |
| Enterprise Value | 164.22M |
| Gross Profit Margin (Quarterly) | -124.6% |
| Profit Margin (Quarterly) | -2.40K% |
| Earnings Yield | -48.44% |
| Normalized Earnings Yield | -48.41 |